Surrozen, Inc. (SRZN)
- Previous Close
9.99 - Open
9.91 - Bid --
- Ask --
- Day's Range
9.83 - 10.43 - 52 Week Range
4.50 - 16.19 - Volume
6,482 - Avg. Volume
16,142 - Market Cap (intraday)
33.363M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-18.41 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.00
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
www.surrozen.comRecent News: SRZN
Performance Overview: SRZN
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRZN
Valuation Measures
Market Cap
33.42M
Enterprise Value
8.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.11
Enterprise Value/Revenue
-0.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.70%
Return on Equity (ttm)
-80.66%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.58M
Diluted EPS (ttm)
-18.41
Balance Sheet and Cash Flow
Total Cash (mrq)
27.29M
Total Debt/Equity (mrq)
9.25%
Levered Free Cash Flow (ttm)
-19.55M